Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders

Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. ENLV, was a guest speaker at Benzinga’s All Access on June 17th, 2022. 

Enlivex Therapeutics is a clinical stage, macrophage reprogramming immunotherapy company developing Allocetra - an off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.

Watch full interview here

Feature photo